Regeneron Sells Cholesterol Drug’s International Rights to Ultragenyx
Ultragenyx has gained the nonU.S. rights to market Regeneron’s Evkeeza (evinacumab), a first-in-class drug treatment for homozygous familial hypercholesterolemia, a life-threatening genetic disorder.
The drug is indicated along with diet and other low-density lipoprotein-cholesterol lowering therapies for people 12 years and older with the rare disorder.
Under the deal, Regeneron will receive an upfront payment of $30 million and is eligible to receive an additional $63 million in milestone-based payments, as well as royalties on net international sales.
Regeneron will continue to sell Evkeeza in the U.S., where it was launched in February 2021. Ultragenyx is expected to focus on the EU market, where the drug received marketing authorization for the indication in June 2021.